Skip to main content

Table 2 Analysis of magnesium concentration in monocytes and lymphocytes (in mg/L) and in erythrocytes (in mmol/L)

From: Higher bioavailability of magnesium citrate as compared to magnesium oxide shown by evaluation of urinary excretion and serum levels after single-dose administration in a randomized cross-over study

Parameter Time point Study product Mean (SD) ANOVA
     Adj. mean difference 95% CI p-value
Mg in monocytes and lymphocytes predose Biolectra 0.11 (0.034) 0.013 (−0.004, 0.030) 0.1235
Verla 0.12 (0.043)
9 h Biolectra 0.12 (0.034) −0.005 (−0.012, 0.002) 0.1614
Verla 0.11 (0.040)
24 h Biolectra 0.11 (0.029) −0.007 (−0.018, 0.005) 0.2424
Verla 0.11 (0.023)
Mg in erythrocytes Predose Biolectra 2.27 (0.400) −0.022 (−0.233, 0.189) 0.8294
Verla 2.24 (0.439)
9 h Biolectra 2.09 (0.287) −0.001 (−0.116, 0.113) 0.9784
Verla 2.09 (0.269)
24 h Biolectra 2.10 (0.353) 0.028 (−0.106, 0.162) 0.6655
Verla 2.13 (0.318)
  1. CI confidence interval, Mg magnesium, SD standard deviation; Biolectra = Biolectra® Magnesium 300 mg Kapseln; Verla = Magnesium Verla® purKaps. Adjusted mean difference, 95% CI and p-value are based on an ANOVA model with study product, sequence, period and subject within sequence as considered effects. Statistical significance at a level of 5% is given if the 95% confidence interval of the adjusted mean difference does not include 0, respectively if the p-value is <0.05